mRNA

T cells
#Cancer research #Icahn School of Medicine #Immunotherapy #Melanoma #mRNA #Oncology #Solid tumours

RNA strategy activates dendritic cells and eradicates melanoma tumours

Investigators at the Icahn School of Medicine at Mount Sinai have designed an RNA-based strategy to activate dendritic cells that eradicated tumours and prevented their recurrence in mouse models of melanoma. The findings, which suggest that the approach has the potential to be effective against tumours… Read More

#Cancer Research #Editor's Choice #News

#Drug development #Elegen #Events #mRNA #mRNA-based vaccines #Webinar

Further insight into breakthroughs in mRNA drug discovery 

DDW recently hosted Where are the breakthroughs in mRNA drug discovery and development? In this webinar, sponsored by Elegen, attendees learnt about the breakthroughs in mRNA drug discovery and development. Watch this on demand now.   Due to technical difficulties, Carsten Rudolph, Managing Director and CEO of Ethris, was unable to… Read More

#Exclusive Content

microRNA
#Drug development #Elegen #Events #mRNA #mRNA-based vaccines #Webinar

Webinar: The breakthroughs in mRNA drug discovery

Hosted by DDW and sponsored by Elegen, “Where are the breakthroughs in mRNA drug discovery and development?” will be free to attend on July 19 at 8AM PDT / 11AM EST / 4PM BST / 5PM CET. Join this free webinar to learn about the opportunities in… Read More

Webinar date:
Brought to you by The Jackson Laboratory
#News

#Artificial intelligence (AI) #Cell and gene therapy #Machine learning #Monoclonal antibodies #mRNA #Precision medicine

Right on target: The shift to precision pharmaceuticals

By DDW Editor Reece Armstrong. If there’s one thing I would take from the Summer 2023 issue of Drug Discovery World, it would be that the application of technologies and processes throughout the pharmaceutical industry are changing how scientists pursue the development of therapies. Artificial intelligence (AI), gene editing, synthetic… Read More

#Exclusive Content

#Drug development #Elegen #Events #mRNA #mRNA-based vaccines #Webinar

What does the future hold for mRNA therapeutics? Register now

Hosted by DDW and sponsored by Elegen, “Where are the breakthroughs in mRNA drug discovery and development?” will be free to attend on July 19 at 8AM PDT / 11AM EST / 4PM BST / 5PM CET. Join this free webinar to learn about the opportunities in… Read More

Webinar date:
Brought to you by The Jackson Laboratory
#News

Lipid nanoparticle mRNA vaccine
#In Focus Report #mRNA #mRNA-based vaccines #Thermo Fisher Scientific

In depth eReport – mRNA: New uses for this exciting technology

Although the concept of messenger ribonucleic acid (mRNA) as a potential therapeutic technology has been around for decades, it took a global pandemic to give the mRNA platform the necessary shot in the arm and development has proceeded at astonishing speed since. Download this In Focus eReport… Read More

#News

#In Focus Report #mRNA #mRNA-based vaccines #Thermo Fisher Scientific

mRNA: New uses for this exciting technology

Download this In Focus eReport to gain a full understanding of the current market for mRNA vaccines and therapeutics and the areas of greatest commercial potential for the future. The eReport includes: In-depth analysis of regional markets An overview of the likely challenges and opportunities The companies taking the lead… Read More

#DDW eBooks #DDW In Focus eReports #Intelligence

RNA
#Drug development #Elegen #Events #mRNA #mRNA-based vaccines #Webinar

Learn about the opportunities in mRNA drug discovery

Hosted by DDW and sponsored by Elegen, “Where are the breakthroughs in mRNA drug discovery and development?” will be free to attend on July 19 at 8AM PDT / 11AM EST / 4PM BST / 5PM CET. Join this free webinar to learn about the opportunities in… Read More

Webinar date:
Brought to you by The Jackson Laboratory
#News

Lipid nanoparticle mRNA vaccine
#Arcturus #BioNTech #Covid-19 vaccine #Moderna #mRNA #mRNA-based vaccines

The companies taking the lead on mRNA

DDW’s Diana Spencer takes a closer look at three companies hoping to be the first to bring new mRNA therapeutics to the market. Although the concept of using mRNA to make therapeutics or vaccines has been around for decades, it took the urgency of a global pandemic for it to… Read More

#Exclusive Content

mRNA
#Drug development #Elegen #Events #mRNA #mRNA-based vaccines #Webinar

Webinar: Where are the breakthroughs in mRNA?

Hosted by DDW and sponsored by Elegen, “Where are the breakthroughs in mRNA drug discovery and development?” will be free to attend on July 19 at 8AM PDT / 11AM EST / 4PM BST / 5PM CET. Join this free webinar to learn about the opportunities in mRNA drug discovery… Read More

Webinar date:
Brought to you by The Jackson Laboratory
#News

mRNA
#Drug development #Drug discovery #mRNA #mRNA-based vaccines

Where are the breakthroughs in mRNA drug discovery and development?

In this on demand webinar, hosted by DDW and sponsored by Elegen, learn about the breakthroughs in mRNA drug discovery and development. You will hear from Carsten Rudolph, Managing Director and CEO of Ethris, Klaas Zuideveld, CEO of Versameb, as well as Matthew Hill, Founder and CEO of Elegen. What… Read More

Webinar date:
Sponsored by Elegen
#Webinars

#Biopharmaceuticals #Immunology / Virology & Vaccines #Investment #invoX Pharma #mRNA #mRNA-based vaccines #Next generation sequencing #Sino Biopharmaceutical

pHion to progress its lead program into the clinic 

invoX Pharma, a UK-based wholly-owned subsidiary of Sino Biopharmaceutical, with an advancing pipeline of innovative products, has completed a second tranche of investment in pHion Therapeutics, a next-generation mRNA vaccine company.   pHion is developing a pipeline of therapeutic and prophylactic vaccines focussed on oncology and infectious diseases. The company’s proprietary… Read More

#Business & Investment #News

Lipid nanoparticle mRNA vaccine
#Advanced Therapies #Cell and gene therapy #Moderna #mRNA #Phase II trial #Rare disease

Positive initial data on first mRNA therapy for propionic acidemia

Moderna has reported encouraging interim data from its Phase I/II trial of mRNA-3927, an mRNA therapy for rare metabolic disorder propionic acidemia (PA). The data was presented at the 2023 American Society of Gene & Cell Therapy (ASGCT) Annual Meeting. The ongoing global Phase… Read More

#News #Trending News

Influenza virus
#Immunology / Virology & Vaccines #Influenza #mRNA #mRNA-based vaccines #National Institute of Allergy and Infectious Diseases #Phase I trial

mRNA universal influenza vaccine enters clinical trials

A clinical trial of an experimental universal influenza vaccine developed by researchers at the National Institute of Allergy and Infectious Diseases’ (NIAID) Vaccine Research Center (VRC) has begun enrolling volunteers at Duke University in Durham, North Carolina. This Phase I trial will test the experimental vaccine,… Read More

#News #Trending News

#Age-related diseases (ARDs) #Ageing #AI #Biotechnology #Business #Clinical trials #mRNA

Podcast: The impact of technology on drug discovery

This is the latest episode of the free DDW narrated podcast, “The impact of technology on drug discovery”. It covers two articles written for Volume 23, Issue 2 – Spring 2022 of DDW. They are called “Talking Tech” and “Rejuvenation biotech: Can… Read More

#News

#AACR #AACR 2023 #Awards #Cancer immunotherapy #Cancer research #Immunology / Virology & Vaccines #mRNA

Sunday 16 April at AACR Annual Meeting 2023

DDW’s Megan Thomas rounds up highlights from Sunday 16 April at AACR 2023, from promising trial results for a personalised mRNA-based cancer vaccine to winners of lifetime achievement awards. Opening plenary session Sunday’s opening plenary session borrowed its name from the Annual Meeting theme, “Advancing the Frontiers of Cancer Science… Read More

#News